Literature DB >> 12538844

Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.

Ignacio Moreno1, Ricardo Caballero, Teresa González, Cristina Arias, Carmen Valenzuela, Isabel Iriepa, Enrique Gálvez, Juan Tamargo, Eva Delpón.   

Abstract

We studied the effects of irbesartan, a selective angiotensin II type 1 receptor antagonist, on human ether-a-go-go-related gene (HERG), KvLQT1+minK, hKv1.5, and Kv4.3 channels using the patch-clamp technique. Irbesartan exhibited a low affinity for HERG and KvLQT1+minK channels (IC(50) = 193.0 +/- 49.8 and 314.6 +/- 85.4 microM, respectively). In hKv1.5 channels, irbesartan produced two types of block, depending on the concentration tested. At 0.1 microM, irbesartan inhibited the current in a time-dependent manner (22 +/- 3.9% at +60 mV). The blockade increased steeply with channel activation increasing at more positive potentials. However, at 10 microM, irbesartan induced a time-independent blockade that occurred in the range of potentials of channel opening, reaching its maximum at approximately 0 mV, and remaining unchanged at more positive potentials (24.0 +/- 1.0% at +60 mV). In Kv4.3 currents, irbesartan produced a concentration-dependent block, which resulted in two IC(50) values (1.0 +/- 0.1 nM and 7.2 +/- 0.6 microM). At 1 microM, it inhibited the peak current and accelerated the time course of inactivation, decreasing the total charge crossing the membrane (36.6 +/- 7.8% at +50 mV). Irbesartan shifted the inactivation curve of Kv4.3 channels, the blockade increasing as the amount of inactivated channels increased. Molecular modeling was used to define energy-minimized dockings of irbesartan to hKv1.5 and HERG channels. In conclusion, irbesartan blocks Kv4.3 and hKv1.5 channels at therapeutic concentrations, whereas the blockade of HERG and KvLQT1+minK channels occurred only at supratherapeutic levels. In hKv1.5, a receptor site is apparent on each alpha-subunit of the channel, whereas in HERG channels a common binding site is present at the pore.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538844     DOI: 10.1124/jpet.102.042325

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

Authors:  Imju Jeong; Shin Hee Yoon; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-27       Impact factor: 3.000

2.  Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Pflugers Arch       Date:  2010-08-24       Impact factor: 3.657

3.  Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.

Authors:  Ricardo Gómez; Lucía Núñez; Ricardo Caballero; Miguel Vaquero; Juan Tamargo; Eva Delpón
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

4.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

5.  Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.

Authors:  Daniel Scherer; Katharina von Löwenstern; Edgar Zitron; Eberhard P Scholz; Ramona Bloehs; Sven Kathöfer; Dierk Thomas; Alexander Bauer; Hugo A Katus; Christoph A Karle; Claudia Kiesecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

6.  Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients.

Authors:  Yingkai Cui; Changsheng Ma; Deyong Long; Liping Wang; Xuebin Cao; Ghang Zhang
Journal:  Exp Ther Med       Date:  2014-12-16       Impact factor: 2.447

7.  The role of the renin-angiotensin system blocking in the management of atrial fibrillation.

Authors:  Brett Cliff; Naveed Younis; Salam Hama; Handrean Soran
Journal:  J Drug Assess       Date:  2012-03-05

Review 8.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18

9.  The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.

Authors:  Fazhong He; Jianquan Luo; Zhiying Luo; Lan Fan; Yijing He; Dingliang Zhu; Jinping Gao; Sheng Deng; Yan Wang; Yuesheng Qian; Honghao Zhou; Xiaoping Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  Involvement of Kv1.5 protein in oxidative vascular endothelial cell injury.

Authors:  Wen-Liang Chen; Xiong-Qing Huang; Li-Yan Zhao; Jie Li; Jian-Wen Chen; Ying Xiao; Yun-Ying Huang; Jie Liu; Guan-Lei Wang; Yong-Yuan Guan
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.